Integrins in cardiac fibrosis.
Extracellular matrix
Fibroblast
Fibrosis
Heart failure
Integrin
Leukocyte
Myocardial infarction
Journal
Journal of molecular and cellular cardiology
ISSN: 1095-8584
Titre abrégé: J Mol Cell Cardiol
Pays: England
ID NLM: 0262322
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
10
03
2022
revised:
10
07
2022
accepted:
18
07
2022
pubmed:
26
7
2022
medline:
15
11
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Cells sense mechanical stress and changes in their matrix environment through the integrins, a family of heterodimeric surface receptors that bind to extracellular matrix ligands and trigger cytoskeletal remodeling, while transducing a wide range of intracellular signals. Integrins have been extensively implicated in regulation of inflammation, repair and fibrosis in many different tissues. This review manuscript discusses the role of integrin-mediated cascades in myocardial fibrosis. In vitro studies have demonstrated that β1 and αv integrins play an important role in fibrogenic conversion of cardiac fibroblast, acting through direct stimulation of FAK/Src cascades, or via accentuation of growth factor signaling. Fibrogenic actions of αv integrins may be mediated, at least in part, through pericellular activation of latent TGF-β stores. In vivo evidence supporting the role of integrin heterodimers in fibrotic cardiac remodeling is limited to associative evidence, and to experiments using pharmacologic inhibitors, or global loss-of-function approaches. Studies documenting in vivo actions of integrins on fibroblasts using cell-specific strategies are lacking. Integrin effects on leukocytes may also contribute to the pathogenesis of fibrotic myocardial responses by mediating recruitment and activation of fibrogenic macrophages. The profile and role of integrins in cardiac fibrosis may be dependent on the underlying pathologic condition. Considering their cell surface localization and the availability of small molecule inhibitors, integrins may be attractive therapeutic targets for patients with heart failure associated with prominent fibrotic remodeling.
Identifiants
pubmed: 35872324
pii: S0022-2828(22)00137-7
doi: 10.1016/j.yjmcc.2022.07.006
pii:
doi:
Substances chimiques
Integrins
0
Transforming Growth Factor beta
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-13Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL076246
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL085440
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL149407
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.